Evidence map›Paper›PMID 39585602›Full record

ArticleJournal of natural medicines2025

Sulfoquinovosyl diacylglycerol, a component of Holy Basil Ocimum tenuiflorum, inhibits the activity of the SARS-CoV-2 main protease and viral replication in vitro.

Hinako Koze, Masayuki Sudoh, Satoaki Onitsuka, Hiroaki Okamura, Takeshi Ishikawa, Fumito Tani, Yukako Miyata-Yabuki, Mikako Shirouzu, Masanori Baba, Mika Okamoto and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hinako KozeDepartment of Chemistry, Graduate School of Science and Engineering, Kagoshima University, 1-21-35 Korimoto, Kagoshima, 890-0065, Japan.
Masayuki SudohDepartment of Translational Research, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Satoaki OnitsukaDepartment of Chemistry, Graduate School of Science and Engineering, Kagoshima University, 1-21-35 Korimoto, Kagoshima, 890-0065, Japan.
Hiroaki OkamuraDepartment of Chemistry, Graduate School of Science and Engineering, Kagoshima University, 1-21-35 Korimoto, Kagoshima, 890-0065, Japan.
Takeshi IshikawaDepartment of Chemistry, Biotechnology, and Chemical Engineering, Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Korimoto, Kagoshima, 890-0065, Japan.
Fumito TaniInstitute for Materials Chemistry and Engineering, Kyushu University, 744 Motooka Nishi-ku, Fukuoka, 819-0395, Japan.
Yukako Miyata-YabukiDrug Discovery Structural Biology Platform Unit, Center for Biosystems Dynamics Research, RIKEN, 1-7-22 Suehiro, Tsurumi, Yokohama, Kanagawa, 230-0045, Japan.
Mikako ShirouzuDrug Discovery Structural Biology Platform Unit, Center for Biosystems Dynamics Research, RIKEN, 1-7-22 Suehiro, Tsurumi, Yokohama, Kanagawa, 230-0045, Japan.
Masanori BabaDivision of Infection Control Research, Center for Advanced Science Research and Promotion, Kagoshima University, 1-21-24, Korimoto, Kagoshima, 890-8580, Japan.
Mika OkamotoDivision of Infection Control Research, Center for Advanced Science Research and Promotion, Kagoshima University, 1-21-24, Korimoto, Kagoshima, 890-8580, Japan.
Toshiyuki HamadaDepartment of Chemistry, Graduate School of Science and Engineering, Kagoshima University, 1-21-35 Korimoto, Kagoshima, 890-0065, Japan. thamada@sci.kagoshima-u.ac.jp.ORCID http://orcid.org/0000-0002-7631-7974

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The persistence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the emergence of new mutant strains continue to present a substantial threat with potential for future pandemics. Safe, effective, and readily available COVID-19 therapeutics are urgently needed to prepare for future coronavirus pandemics. To help identify new antiviral agents, the present study focused on natural products in the extracts of Holy Basil, Ocimum tenuiflorum L., which show potential inhibitory effects against the SARS-CoV-2 main protease (M

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesOcimumOcimum basilicumPlant ExtractsSARS-CoV-2Virus ReplicationAnimalsChlorocebus aethiopsCOVID-19COVID-19 Drug TreatmentHumansMolecular Docking SimulationVero CellsAntiviral AgentsCoronavirus 3C ProteasesPlant ExtractsMpro inhibitorOcimum tenuiflorum L.SARS-CoV-2 main proteaseSulfoquinovosyl diacylglycerol

Identifiers

PMID39585602
PMCPMC11735596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.